AccScience Publishing / GTM / Volume 2 / Issue 4 / DOI: 10.36922/gtm.2209
Cite this article
39
Download
479
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Prognostic evaluation of relapse based on squamous cell carcinoma antigen, CXCR2, and CD44V6 blood levels in patients with Stage I–II squamous cell lung cancer

Anatoli D. Tahanovich1* Mikalai M. Kauhanka1 Zhanna A. Rutkovskaya1 Ekaterina A. Khotko1 Oxana V. Gotko2 Violetta I. Prokhorova2
Show Less
1 Department of Biological Chemistry, Medical Faculty of International Studentsian State Medical University, Minsk, Belarus
2 Department of Laboratory Diagnostics, N.N. Alexandrov National Cancer Center of Belarus, a/g Lesnoy, Minsk, Belarus
Global Translational Medicine 2023, 2(4), 2209 https://doi.org/10.36922/gtm.2209
Submitted: 8 November 2023 | Accepted: 18 December 2023 | Published: 28 December 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Lung cancer, the leading cause of cancer-related mortality, predominantly exists as non-small cell lung cancer, accounting for approximately 85% of cases and comprising adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma as the three most prevalent histological subtypes. This study focused on investigating pre- and post-operative concentrations of SCC antigen in blood serum, as well as the percentage of CXCR2-containing lymphocytes and CD44v6-containing monocytes in blood cell populations among patients with Stages I–II squamous cell lung cancer (SCLC) within 1 year after tumor resection. The primary objective was to assess their potential for predicting relapse. The study cohort comprised 57 patients (32 men and 25 women) with newly diagnosed squamous cell lung cancer (21 at stage I and 36 at stage II). Following tumor resection, categorized as R0 in terms of surgical intervention, all parameters were examined before surgery and at 3 weeks, 3 months, and 6 months postoperatively. Analysis revealed that the probability of relapse could be accurately predicted, ranging from 68.4% to 89.5%, based on differences in SCC antigen concentration, the percentage of lymphocytes with CXCR2, and monocytes with the CD44v6 receptor during various post-operative intervals. Subsequent regression analysis and the formulation of a combined model incorporating the above-mentioned parameters led to an enhanced predictive value for tumor recurrence, reaching 96.5% accuracy (with specificity at 95.6% and sensitivity at 100%). These results indicate the potential utility of the combined model as an additional marker for predicting postoperative relapse in patients with Stage I–II SCLC.

Keywords
Squamous cell lung cancer
Squamous cell carcinoma
CXCR2
CD44v6
Post-operative relapse
Prognosis
Funding
Ministry of Health of the Republic of Belarus
References
  1. Sung H, Ferlay J, Siegel RL, et al., 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71: 209–249. https://doi.org/10.3322/caac.21660

 

  1. Araghi M, Mannani R, Maleki AH, et al., 2023, Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int, 23: 162. https://doi.org/10.1186/s12935-023-02990-y

 

  1. Wang CY, Huang MS, Huang MH, et al., 2010, Persistently high serum carcinoembryonic antigen levels after surgery indicate poor prognosis in patients with stage I non-small-cell lung cancer. J Surg Res, 163: e45–e50. https://doi.org/10.1016/j.jss.2010.04.039

 

  1. Kerr KM, Nicolson MC, 2013, Prognostic factors in resected lung carcinomas. EJC Suppl, 11: 137–149. https://doi.org/10.1016/j.ejcsup.2013.07.023

 

  1. Remon J, Soria JC, Peters S, 2021, Early and locally advanced non-small-cell lung cancer: An update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol, 32: 1637–1642. https://doi.org/10.1016/j.annonc.2021.08.1994

 

  1. Tahanovich AD, Kauhanka NN, Prohorova VI, et al., 2022, Determination of the risk of tumor progression in patients with early stages of adenocarcinoma and squamous cell lung carcinoma based on laboratory parameters. Biochem Moscow Suppl Ser B, 16: 154–163. https://doi.org/10.1134/S1990750822020081

 

  1. Kuribayashi K, Funaguchi N, Nakano T, 2016, Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma. J Cancer Res Ther, 12: 528–534. https://doi.org/10.4103/0973-1482.174185

 

  1. Suminami Y, Nawata S, Kato H, 1998, Biological role of SCC antigen. Tumour Biol, 19: 488–493. https://doi.org/10.1159/000030042

 

  1. Zhang W, Wang H, Sun M, et al., 2020, CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun (Lond), 40: 69–80. https://doi.org/10.1002/cac2.12010

 

  1. Chen C, Zhao S, Karnad A, et al., 2018, The biology and role of CD44 in cancer progression: Therapeutic implications. J Hematol Oncol, 11: 64. https://doi.org/10.1186/s13045-018-0605-5

 

  1. Parikh R, Mathai A, Parikh S, et al., 2008, Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol, 56: 45–50. https://doi.org/10.4103/0301-4738.37595

 

  1. Lagiou P, Trichopoulos D, 2011, Inflammatory biomarkers and risk of lung cancer. J Natl Cancer Inst, 103: 1073–1075. https://doi.org/10.1093/jnci/djr220

 

  1. Spaks A, 2017, Role of CXC group chemokines in lung cancer development and progression. J Thorac Dis, 9: S164–S171. https://doi.org/10.21037/jtd.2017.03.61

 

  1. Zhao S, He JL, Qiu ZX, et al., 2014, Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: A meta-analysis. Asian Pac J Cancer Prev, 15: 6761–6766. https://doi.org/10.7314/apjcp.2014.15.16.6761

 

  1. Luo Z, Wu RR, Lu L, et al., 2014, Prognostic value of CD44 expression in non-small cell lung cancer: A systematic review. Int J Clin Exp Pathol, 7: 3632–3646.

 

  1. Zissimopoulos A, Stellos K, Permenopoulou V, et al., 2007, The importance of the tumor marker CYFRA 21–1 in patients with lung cancer after surgery or chemotherapy. Hell J Nucl Med, 10: 62–66.

 

  1. Yeh JJ, Liu FY, Hsu WH, et al., 2002, Monitoring cytokeratin fragment 19 (CYFRA 21–1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection. Lung, 180: 273–279. https://doi.org/10.1007/s004080000101

 

  1. Sawabata N, Maeda H, Yokota S, et al., 2004, Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: Subnormal levels as an indicator of favorable prognosis. Cancer, 101: 803–809. https://doi.org/10.1002/cncr.20421

 

  1. Ozeki N, Fukui T, Taniguchi T, et al., 2014, Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer. Eur J Cardiothorac Surg, 45: 687–692. https://doi.org/10.1093/ejcts/ezt424

 

  1. Duan X, Cui Y, Li H, et al., 2015, High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21–1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer. Indian J Cancer, 52: E158–E163. https://doi.org/10.4103/0019-509X.186564

 

  1. Barak V, Holdenrieder S, Nisman B, et al., 2010, Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomark, 6: 191–196. https://doi.org/10.3233/CBM-2009-0129

 

  1. Muley T, He Y, Rolny V, et al., 2019, Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21–1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. Lung Cancer, 130: 194–200. https://doi.org/10.1016/j.lungcan.2019.02.017

 

  1. Pang L, Wang J, Jiang Y, et al., 2013, Decreased levels of serum cytokeratin 19 fragment CYFRA 21–1 predict objective response to chemotherapy in patients with non-small cell lung cancer. Exp Ther Med, 6: 355–360. https://doi.org/10.3892/etm.2013.1171

 

  1. Holdenrieder S, Wehnl B, Hettwer K, et al., 2017, Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: A systematic review and meta-analysis. Br J Cancer, 116: 1037–1045. https://doi.org/10.1038/bjc.2017.45

 

  1. Takeuchi S, Nonaka M, Kadokura M, et al., 2003, Prognostic significance of serum squamous cell carcinoma antigen in surgically treated lung cancer. Ann Thorac Cardiovasc Surg, 9: 98–104. https://pubmed.ncbi.nlm.nih.gov/12732086

 

  1. Chen IH, Liao CT, Wang HM, et al., 2014, Using SCC antigen and CRP levels as prognostic biomarkers in recurrent oral cavity squamous cell carcinoma. PLoS One, 9: e103265. https://doi.org/10.1371/journal.pone.0103265

 

  1. Choi KH, Lee SW, Yu M, et al., 2019, Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: A multi-institutional analysis. J Gynecol Oncol, 30: e1. https://doi.org/10.3802/jgo.2019.30.e1

 

  1. Deng Z, Hasegawa M, Yamashita Y, et al., 2012, Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer Sci, 103: 2127–2134. https://doi.org/10.1111/cas.12009

 

  1. Bresalier RS, Grady WM, Markowitz SD, et al., 2020, Biomarkers for Early Detection of colorectal cancer: The early detection research network, a framework for clinical translation. Cancer Epidemiol Biomarkers Prev, 29: 2431–2440. https://doi.org/10.1158/1055-9965.EPI-20-0234

 

  1. Sjoberg DD, Vickers AJ, Assel M, et al., 2018, Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men. Eur Urol, 73: 941–948. https://doi.org/10.1016/j.eururo.2018.02.016

 

  1. Monroy-Iglesias MJ, Crescioli S, Beckmann K, et al., 2022, Antibodies as biomarkers for cancer risk: A systematic review. Clin Exp Immunol, 209: 46–63. https://doi.org/10.1093/cei/uxac030

 

  1. Blanco-Prieto S, De Chiara L, Rodríguez-Girondo M, et al., 2017, Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units. Sci Rep, 7: 41151. https://doi.org/10.1038/srep41151

 

  1. Fahrmann JF, Marsh T, Irajizad E, et al., 2022, Blood- Based Biomarker Panel for Personalized Lung Cancer Risk Assessment. J Clin Oncol, 40: 876–883. https://doi.org/10.1200/JCO.21.01460
Conflict of interest
All authors declare no conflict of interest.
Share
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Published by AccScience Publishing